Researchers conducted a multicenter, randomized clinical trial examining how 12 mg vs 6 mg of dexamethasone affects the number of days alive without life support at 28 days in patients with COVID-19 and severe hypoxemia.
A total of 1,000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation, were included.
Treatment with 12 mg/d of dexamethasone was linked with 22.0 days alive without life support vs 20.5 days in those receiving 6 mg/d of dexamethasone.
Overall, 12 mg of dexamethasone did not link with statistically significant reduction in the number of days alive without life support at 28 days when compared with 6 mg of dexamethasone.
Read the full article on JAMA